The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Pionyr; TriSalus Life Sciences
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
 
Vincent Chung
Consulting or Advisory Role - Perthera
Speakers' Bureau - AstraZeneca; Coherus Biosciences; Ipsen
Research Funding - Merck (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Michael J Pishvaian
No Relationships to Disclose
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
 
Andrew M. Lowy
Consulting or Advisory Role - Clearnote Health; Corcept Therapeutics; Kinnate Biopharma; Rafael Pharmaceuticals; Steba Biotech
Expert Testimony - Merck
Travel, Accommodations, Expenses - Pfizer
 
Davendra Sohal
Honoraria - Foundation Medicine
Consulting or Advisory Role - Ability Pharma; AstraZeneca/MedImmune; Bayer; Torus Pharma
Speakers' Bureau - Genentech; Incyte
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst)
 
Sarah Colby
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals